Blueprint Medicines (NASDAQ:BPMC) Given New $130.00 Price Target at Stifel Nicolaus

Blueprint Medicines (NASDAQ:BPMC) had its price target lifted by Stifel Nicolaus from $120.00 to $130.00 in a research report released on Friday, Benzinga reports. The brokerage currently has a buy rating on the biotechnology company’s stock.

Several other research analysts also recently commented on the company. HC Wainwright restated a buy rating and set a $125.00 price objective on shares of Blueprint Medicines in a report on Friday. Citigroup lifted their price objective on Blueprint Medicines from $54.00 to $65.00 and gave the company a sell rating in a report on Friday, February 16th. Needham & Company LLC reiterated a buy rating and set a $97.00 target price on shares of Blueprint Medicines in a report on Friday. Wedbush restated an outperform rating and issued a $110.00 price target on shares of Blueprint Medicines in a report on Friday. Finally, Barclays increased their price objective on shares of Blueprint Medicines from $58.00 to $70.00 and gave the company an equal weight rating in a research note on Tuesday, February 13th. Four investment analysts have rated the stock with a sell rating, two have given a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, Blueprint Medicines presently has a consensus rating of Hold and an average target price of $91.57.

Blueprint Medicines Stock Up 2.5 %

Shares of BPMC opened at $93.00 on Friday. The firm has a fifty day moving average price of $90.79 and a 200-day moving average price of $78.80. The company has a debt-to-equity ratio of 1.60, a current ratio of 3.76 and a quick ratio of 3.66. Blueprint Medicines has a 12-month low of $43.89 and a 12-month high of $101.00.

Blueprint Medicines (NASDAQ:BPMC) last released its quarterly earnings data on Thursday, February 15th. The biotechnology company reported ($1.82) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.04) by $0.22. The company had revenue of $71.96 million during the quarter, compared to analysts’ expectations of $67.34 million. Blueprint Medicines had a negative net margin of 203.30% and a negative return on equity of 191.56%. The firm’s quarterly revenue was up 85.5% on a year-over-year basis. During the same period in the previous year, the company earned ($2.65) EPS. On average, equities analysts expect that Blueprint Medicines will post -5.41 EPS for the current year.

Insider Buying and Selling

In other Blueprint Medicines news, Director Jeffrey W. Albers sold 25,073 shares of the stock in a transaction dated Wednesday, March 20th. The stock was sold at an average price of $87.28, for a total value of $2,188,371.44. Following the completion of the sale, the director now directly owns 176,050 shares in the company, valued at $15,365,644. The transaction was disclosed in a document filed with the SEC, which is available at this link. In other Blueprint Medicines news, CEO Kate Haviland sold 12,464 shares of Blueprint Medicines stock in a transaction dated Thursday, March 7th. The stock was sold at an average price of $90.69, for a total transaction of $1,130,360.16. Following the completion of the sale, the chief executive officer now owns 153,177 shares of the company’s stock, valued at approximately $13,891,622.13. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Jeffrey W. Albers sold 25,073 shares of the company’s stock in a transaction that occurred on Wednesday, March 20th. The shares were sold at an average price of $87.28, for a total value of $2,188,371.44. Following the completion of the sale, the director now owns 176,050 shares in the company, valued at approximately $15,365,644. The disclosure for this sale can be found here. Insiders have sold a total of 92,289 shares of company stock worth $8,314,163 in the last ninety days. 3.88% of the stock is owned by insiders.

Institutional Trading of Blueprint Medicines

Hedge funds and other institutional investors have recently made changes to their positions in the business. SG Americas Securities LLC lifted its position in Blueprint Medicines by 1,436.4% during the third quarter. SG Americas Securities LLC now owns 33,478 shares of the biotechnology company’s stock valued at $1,681,000 after purchasing an additional 31,299 shares during the period. Peregrine Capital Management LLC raised its stake in shares of Blueprint Medicines by 2.1% during the 3rd quarter. Peregrine Capital Management LLC now owns 146,663 shares of the biotechnology company’s stock valued at $7,365,000 after buying an additional 3,074 shares during the last quarter. Harbor Capital Advisors Inc. lifted its holdings in shares of Blueprint Medicines by 33.4% in the 3rd quarter. Harbor Capital Advisors Inc. now owns 32,484 shares of the biotechnology company’s stock valued at $1,631,000 after buying an additional 8,131 shares during the period. Bank of New York Mellon Corp lifted its holdings in shares of Blueprint Medicines by 1.6% in the 3rd quarter. Bank of New York Mellon Corp now owns 266,744 shares of the biotechnology company’s stock valued at $13,396,000 after buying an additional 4,127 shares during the period. Finally, Brown Advisory Inc. boosted its stake in shares of Blueprint Medicines by 0.9% in the third quarter. Brown Advisory Inc. now owns 641,039 shares of the biotechnology company’s stock worth $32,193,000 after buying an additional 5,843 shares during the last quarter.

Blueprint Medicines Company Profile

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.